Previous 10 | Next 10 |
JHVEPhoto/iStock Editorial via Getty Images Danish biotech Orphazyme ([[ORPH]] -43.0%) has extended the pre-market losses after the FDA decision not to grant the approval for Arimoclomol the company’s experimental therapy for rare genetic disease Niemann-Pick Disease Type C ((NPC)). Cy...
Gainers: Geron (GERN) +22%, AnPac Bio-Medical Science (ANPC) +20%, CureVac (CVAC) +13%, Crinetics Pharmaceuticals (CRNX) +7%, Seres Therapeutics (MCRB) +7%.Losers: Orphazyme (ORPH) -41%, Athira Pharma (ATHA) -41%, Chinook Therap...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips GEO Group (NYSE: GEO ) is heading higher on Friday following news that the company’s CEO acquired shares of the stock. Source: JosephRouse / Shutterstock.com According to a recent filing with the U.S. S...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Orphazyme (NASDAQ: ORPH ) is getting off to a rough start on Friday, with ORPH stock down more than 50% in pre-market trading. This comes after the Denmark-based biotech company has rocketed higher in recent weeks. In...
Orphazyme (ORPH) -53% on FDA thumbs down for arimoclomol; cuts FY21 outlook.Athira Pharma (ATHA) -30% after the decision to place CEO on temporary leave.Capstone Green Energy (CGRN) -26% on $10M capital raiseCellect Biotechnology (APOP) -9%.Arrival (ARVL) -9...
CureVac (CVAC) -47% as Bill Gates-backed biotech shows below-par efficacy for COVID-19 vaccine candidate.Gaucho Group (VINO) -20%.Creatd (CRTD) -17% after proposing stock offeringNovan (NOVN) -14% after proposing capital raise.Torchlight Energy Resources (TRCH)...
Shares of Orphazyme AS (NASDAQ: ORPH) , a clinical-stage biopharmaceutical company, shot through the roof on Wednesday after the company disclosed a significant sale from one of its largest shareholders. Retail investors, convinced this is a sign the company was preparing for a buyo...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme (NASDAQ: ORPH ) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week, at one p...
AMC Stock Has Shown Traders Why Penny Stocks Are So Strong Penny stocks are one of the highest risk types of assets you can buy in the stock market. One minute you’re looking at a 200% windfall, the next, you might’ve lost your entire position. The crazy part is that this ...
CalypsoArt/iStock via Getty Images Shares of Orphazyme (ORPH) have suddenly shot up 95% in afternoon trading on the eve of an expected FDA decision on its application for Arimoclomol for the treatment of Niemann-Pick Disease Type C ("NPC"). Trading in the stock was already briefly h...
News, Short Squeeze, Breakout and More Instantly...
Orphazyme A/S Company Name:
ORPH Stock Symbol:
NASDAQ Market:
(NewsDirect) hVIVO PLC (AIM:HVO) chief executive Yamin 'Mo' Khan discusses the company's record-breaking financial results in 2023 in an interview with Proactive's Stephen Gunnion. hVIVO announced a 16% year-on-year growth in revenue, reaching £56 million, with an EBITDA margin i...
(NewsDirect) hVIVO chairman Cathal Friel joined Proactive's Stephen Gunnion to discuss the sale of shares in hVIVO PLC by directors, including himself. Friel explained his decision to sell a portion of his shares in hVIVO was to accommodate the high demand from major institutions whil...
(NewsDirect) hVIVO PLC (AIM:HVO) Chief Scientific Officer Andrew Catchpole speaks to Steve Darling from Proactive after the specialist contract research organisation announced it has secured a £6.3 million contract with a biotechnology client for the testing of their antiviral candid...